Semaglutide News and Research

Latest Semaglutide News and Research

GLP-1R agonist liraglutide rapidly improves insulin sensitivity in pre-diabetics, independent of weight loss

A new study published in the journal Diabetes demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat Type 2 diabetes and obesity, can lead to a rapid improvement in insulin sensitivity.

4 Jan 2024

Combination therapy of dapagliflozin and semaglutide shows superior efficacy in type 2 diabetes management

Study demonstrates that combining dapagliflozin and semaglutide significantly improves glycemic control and other health parameters in type 2 diabetes patients, outperforming dapagliflozin alone.

3 Jan 2024

MIT engineers develop 'vibing belly' pill to control appetite and curb obesity

When you eat a large meal, your stomach sends signals to your brain that create a feeling of fullness, which helps you realize it's time to stop eating.

26 Dec 2023

MHRA provides 5 festive top tips for people taking medicines or using medical devices

Christmas and New Year is a time when we particularly want to keep well and stay safe. The Medicines and Healthcare products Regulatory Agency (MHRA) has set out 5 festive top tips for people taking medicines or using medical devices.

21 Dec 2023

Diabetes drug may help women avoid weight gain after quitting smoking

The diabetes drug dulaglutide (Trulicity) may significantly lower a woman's risk of substantial weight gain after she has given up smoking, finds a secondary analysis of clinical trial data, published in the open access journal BMJ Nutrition Prevention & Health.

19 Dec 2023

From diabetes drug to anti-inflammation powerhouse: The unexpected evolution of GLP-1

Research pioneer Dr. Daniel Drucker has much to be proud of, as the GLP-1-based diabetes drugs hailing from his early research are named 2023 breakthrough of the year by the Science Magazine.

18 Dec 2023

Science’s Breakthrough of the Year: GLP-1 agonists can blunt obesity-associated health problems

Science has named the development of glucagon like peptide-1 (GLP-1) agonists and this year's discovery that these drugs can blunt obesity-associated health problems as its 2023 Breakthrough of The Year.

15 Dec 2023

How safe are GLP-1R agonists in early pregnancy?

JAMA Internal Medicine study examines the safety of GLP-1 receptor agonists and other second-line antidiabetic medications during early pregnancy, finding no significant increase in congenital anomalies compared to insulin use.

14 Dec 2023

UK drug regulators failing to protect patients from harmful weight loss

UK organizations responsible for protecting the public from prescription-only drug adverts are putting patients at risk from the harms of weight loss drugs by not enforcing the law, reveals an investigation published by The BMJ today.

14 Dec 2023

Poll: Vast majority of older adults think health insurers should cover obesity medications

The vast majority of older adults – 83% -- think health insurers should cover medications that can help people with obesity manage their weight, a new poll of people age 50 to 80 finds.

13 Dec 2023

Tirzepatide shows success in maintaining weight loss in obese adults

Study finds that the anti-obesity medication tirzepatide effectively maintains weight loss in obese adults, offering a promising approach to managing obesity and related health complications.

12 Dec 2023

Adherence to second-line drugs for Type 2 diabetes can be hit or miss, study reports

Most patients with Type 2 diabetes will end up needing to add a second-line medication after metformin -; the go-to primary drug for glucose management -; to control their blood sugar levels.

12 Dec 2023

Tirzepatide maintains weight loss and improves cardiometabolic health in SURMOUNT-4 trial

The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led by researchers at Weill Cornell Medicine and NewYork-Presbyterian found that people who stopped taking the medication regained much of that weight within a year.

11 Dec 2023

Second-line diabetes drugs safe for babies? New study offers reassurance

Infants born to women with pre-gestational type 2 diabetes who take second-line non-insulin antidiabetic medications (ADMs) during pregnancy are at no higher risk of major congenital malformations (MCMs) than infants born to those who take insulin, according to a new study led by Harvard T.H. Chan School of Public Health.

11 Dec 2023

Study explores the intricate gut-brain-liver connection and its impact on health

Study reviews the gut-brain-liver axis, revealing the complex interplay between these organs in health and disease and the implications for therapeutic interventions, focusing on how gut microbiota affects liver and brain health.

10 Dec 2023

New insights into how anti-obesity drugs could help prevent kidney disease

Data from Australian researchers could partly explain why a trial of a new drug for diabetes, was recently halted because it was found to be so effective.

8 Dec 2023

A class of diabetes medications may reduce the risk of colorectal cancer

A groundbreaking study by researchers at Case Western Reserve University suggests a class of medications used to treat type 2 diabetes may also reduce the risk of colorectal cancer (CRC).

7 Dec 2023

Groundbreaking studies indicate Semaglutide and Tirzepatide may reduce alcohol consumption in individuals with obesity

The impact of semaglutide and tirzepatide and glucagon-like peptide-1 receptor agonist medications on alcohol consumption.

1 Dec 2023

Exploring 'food noise': Study sheds light on eating thoughts and obesity treatment breakthroughs

Study delves into the concept of 'food noise,' referring to persistent thoughts about eating, and assesses its impact on eating behaviors and obesity treatments. It explores how GLP-1RAs, a class of drugs used for weight management, might influence food cue reactivity, potentially offering new insights into obesity treatment and the psychological aspects of eating behaviors.

30 Nov 2023

The role of the brainstem in appetite suppression

The role of the brainstem in appetite suppression.

28 Nov 2023

Semaglutide News and Research

Latest Semaglutide News and Research

GLP-1R agonist liraglutide rapidly improves insulin sensitivity in pre-diabetics, independent of weight loss

Combination therapy of dapagliflozin and semaglutide shows superior efficacy in type 2 diabetes management

MIT engineers develop 'vibing belly' pill to control appetite and curb obesity

MHRA provides 5 festive top tips for people taking medicines or using medical devices

Diabetes drug may help women avoid weight gain after quitting smoking

From diabetes drug to anti-inflammation powerhouse: The unexpected evolution of GLP-1

Science’s Breakthrough of the Year: GLP-1 agonists can blunt obesity-associated health problems

How safe are GLP-1R agonists in early pregnancy?

UK drug regulators failing to protect patients from harmful weight loss

Poll: Vast majority of older adults think health insurers should cover obesity medications

Tirzepatide shows success in maintaining weight loss in obese adults

Adherence to second-line drugs for Type 2 diabetes can be hit or miss, study reports

Tirzepatide maintains weight loss and improves cardiometabolic health in SURMOUNT-4 trial

Second-line diabetes drugs safe for babies? New study offers reassurance

Study explores the intricate gut-brain-liver connection and its impact on health

New insights into how anti-obesity drugs could help prevent kidney disease

A class of diabetes medications may reduce the risk of colorectal cancer

Groundbreaking studies indicate Semaglutide and Tirzepatide may reduce alcohol consumption in individuals with obesity

Exploring 'food noise': Study sheds light on eating thoughts and obesity treatment breakthroughs

The role of the brainstem in appetite suppression

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Semaglutide News and Research

Latest Semaglutide News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in